Table 1.
Patients’ baseline characteristics.
| Characteristics | |
|---|---|
| Patients, n | 93 |
| Women—n (%) | 86 (92.4) |
| Age—years | 35 ± 11 |
| Range—years | 19–58 |
| Ethnicity—n (%) | |
| European | 40 (43) |
| North African | 23 (24.7) |
| African | 23 (23.7) |
| Asian | 8 (8.6) |
| Characteristics at kidney biopsy | |
| Serum creatinine—μmol/L | 92.1 ± 68.5 |
| eGFR—mL/min/1.73 m2 | 91.4 ± 39.2 |
| UPCR—g/g | 2.34 ± 2.23 |
| SLE vintage | |
| First flare of SLE—n (%) | 21 (22.6) |
| Pre-existing SLE—n% | 72 (77.4) |
| Disease duration—years | 10.6 ± 8.5 |
| First renal flare—n (%) | 55 (59.1) |
| LN duration—years | 8.2 ± 6.9 |
| Kidney biopsies—n (%) | 93 |
| Class ISN/RPS 2003 | |
| I | 1 (1.1) |
| II | 6 (6.5) |
| III-A or -A/C ± V | 22 (23.7) |
| III-C ±V | 5 (5.4) |
| IV-A or -A/C ± V | 33 (35.5) |
| IV-C ±V | 2 (2.2) |
| Pure V | 21 (22.6) |
| VI | 3 (3.2) |
| Group | |
| Active LN | 55 (59.1) |
| Non-active LN | 38 (40.9) |
| IF/TA | |
| F0 | 41 (44.1) |
| F1 | 33 (35.5) |
| F2 | 12 (12.9) |
| F3 | 7 (7.5) |
| Previous treatment for SLE (%) | |
| Hydroxychloroquine | 80.6 |
| Corticosteroids | 77.4 |
| MMF/Mycophenolic acid | 25.8 |
| Azathioprine | 19.4 |
| Cyclophosphamide | 33.3 |
| Rituximab | 8.6 |
| Other | 14 |
| Treatment for SLE at inclusion (%) | |
| Hydroxychloroquine | 68.8 |
| Corticosteroids | 70.1 |
| MMF/Mycophenolic acid | 17.2 |
| Azathioprine | 9.7 |
| Cyclophosphamide | 1.1 |
| Rituximab | 1.1 |
| Other | 2.2 |
| Patients/center—n (%) | |
| Marseille | 37 (39.8) |
| Paris | 53 (57) |
| Toulouse | 3 (3.2) |
Continuous values expressed in mean value ± SD. MMF, mycophenolate mofetil; eGFR, estimated glomerular filtration rate; UPCR, urine protein to creatinine ratio; SLE, Systemic Lupus Erythematosus; LN, Lupus nephritis.